Caris Life Sciences, Inc. · NASDAQ:CAI
Caris Life Sciences — Technical Presentation (2021)
9 slides from Caris Life Sciences's technical presentation, 2021
Slide 1: Utilizing Molecular Profiling to Identify Potential Therapies in Sarcomatoid Lung Cancer
Utilizing Molecular Profiling to Identify Potential Therapies in Sarcomatoid Lung Cancer Jue Wang1, David Arguello2, Zoran Gatalica2, Sandeep Reddy2, Panos Fidias1 1. University of Arizona Cancer Center, Phoenix, AZ; 2. Caris Life Sciences, Irving, TX 655: Utilizing Molecular Profiling to Identify P
Slide 2: Nothing to Disclose
Nothing to Disclose relevant to the abstract 655: Utilizing Molecular Profiling to Identify Potential Therapies in Sarcomatoid Lung Cancer - Panos Fidias
Slide 3: Background - sarcomatoid lung cancer (SLC)
Background - sarcomatoid lung cancer (SLC) • Comprises one percent of all lung malignancies. • NSCLC with sarcoma-like differentiation or component of sarcoma. • Five types per WHO: carcinosarcoma, giant cell, pleomorphic, pulmonary blastoma, spindle cell. • NSCLC regimens and not sarcoma regimens (
Slide 4: Methods – SLC cohort, multiplex testing
Methods – SLC cohort, multiplex testing • A retrospective review of Caris’ database (from 2003 to the present) identified 48 specimens diagnosed as sarcomatoid lung cancer (SLC). • All diagnoses were confirmed by board-certified pathologists. • Gene sequencing (Sanger or next-generation sequencing [
Slide 5: Results – Variants in SLC by NGS or Sanger
Results – Variants in SLC by NGS or Sanger • Mutations (in blue) were considered shown were pathogenic (i.e. tumorigenic). The c-kit variant identified, H697N, was considered a variant of unknown significance or VUS (in yellow). • The EGFR variants were L858R (x1) and exon20ins (x1). The specimen wi
Slide 6: 655: Utilizing Molecular Profiling to Identify Potential Therapies in Sarcomatoid Lung Cancer - Panos
655: Utilizing Molecular Profiling to Identify Potential Therapies in Sarcomatoid Lung Cancer - Panos Fidias 6
Slide 7: High PD-L1 Expression in SLC
High PD-L1 Expression in SLC 655: Utilizing Molecular Profiling to Identify Potential Therapies in Sarcomatoid Lung Cancer - Panos Fidias 7
Slide 8: Results – in situ hybridization (ISH) in SLC
Results – in situ hybridization (ISH) in SLC Distribution in NSCLC based on outside literature Gene Frequency in NSCLC ALK 3 – 7% MET 2-4% ROS1 1% • EGFR amplification may warrant further exploration. Amplification was independent of EGFR mutation. • Presence of MET (i.e. cMET) gene is higher than w
Slide 9: Conclusions
Conclusions • PD-1 and PD-L1 are differentially expressed in sarcomatoid lung cancer, warranting clinical trials with checkpoint inhibitors. • EGFR mutations were rare in this SLC cohort and its clinical significance merits investigation • KRAS mutations are noticeably higher in this SLC cohort, con